Proper subcellular localization is essential to exert the designated function of a protein, not only for endogenous proteins but also transgene-encoded proteins. Post-translational modification is a frequently used method to regulate the subcellular localization of a specific protein. While there are a number of tags that are widely used to direct the target protein to a specific location within a cell, these tags often fail to emulate the dynamics of protein trafficking, necessitating an alternative approach to the direct subcellular localization of transgene-encoded proteins. Here, we report the development of a new synthetic polypeptide protein tag comprised of ten amino acids, which promotes membrane localization of a target protein. This short synthetic peptide tag, named “Palmito-Tag”, induces ectopic palmitoylation on the cysteine residue within the tag, thereby promoting membrane localization of the target proteins without affecting their innate function. We show that the target proteins with the Palmito-Tag are incorporated into the membranous organelles within the cells, including the endosomes, as well as extracellular vesicles. Given the reversible nature of palmitoylation, the Palmito-Tag may allow us to shift the subcellular localization of the target protein in a context-dependent manner. With the advent of therapeutic applications of exosomes and other extracellular vesicles, we believe that the ability to reversibly modify a target protein and direct its deposition to the specific subcellular milieu will help us explore more effective venues to harness the potential of extracellular vesicle-based therapies.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a debilitating disease with a poor prognosis. However, only a limited number of palliative interventions are currently available. To address this unmet need, it is essential to understand the molecular causes of PAH by identifying unique disease-associated populations and their key molecular regulators during disease progression. METHODS: We constructed a single-cell multiome data set at 4 distinct time points during the pathogenesis of pulmonary hypertension (PH) using endothelial cells isolated from the Sugen5416/hypoxia rat model. We assessed the conservation of novel disease-associated endothelial cells by reanalyzing previously reported single-cell RNA sequencing data from human patients with PAH. We validated the functional importance of EBF1 (early B-cell factor 1) in PAH by performing in silico simulations and an in vivo knockdown mediated by a pulmonary endothelium-targeting associated virus. RESULTS: We found that PH progression gradually altered the transcriptional and epigenetic landscape of the pulmonary endothelium in a stage-specific manner, leading to the emergence of a novel disease-associated arterial endothelial population expressing EBF1. A similar endothelial subset was present in human patients with PAH. Immunofluorescence revealed that EBF1 expression was elevated in both human and rat lungs during PH progression. In silico simulations suggested that EBF1 is required for the pathogenic state, and the associated virus-mediated in vivo knockdown of Ebf1 ameliorated the pathological hallmarks of PH, including right ventricular systolic pressure and right ventricular hypertrophy, when delivered either before the onset of PH or after its establishment. CONCLUSIONS: We identified EBF1 as a key transcriptional regulator of a novel disease-associated population in both humans and rats. We further demonstrated that inhibiting EBF1 within the pulmonary endothelium ameliorates the pathological features of PH, suggesting that EBF1 and its transcriptional targets represent a novel and promising therapeutic avenue for PAH.